Legislation & Regulation

In the AMCP Legislative Days 2025 Booklet, learn about AMCP’s position on legislation impacting managed care pharmacy, how to talk to Members of Congress and their staff, and helpful tips for engaging in effective dialogue.

On May 22, 2025, the President’s Make America Healthy Again Commission published the MAHA report. The report raises concerns about the chronic childhood disease, processed food, environmental chemicals, lack of physical activity, mental health, and overmedicalization of American children.

On May 12, 2025, President Trump signed an Executive Order (EO) requiring agencies to take steps to encourage manufacturers to provide most-favored-nation pricing for prescription drugs.

This month, the House and Senate reached an agreement on a concurrent budget resolution, after weeks of back-and-forth negotiations over topline spending and savings numbers.

On April 16, 2025, the Centers for Medicare and Medicaid Services (CMS) issued guidance on CY 2026 Part D Formulary Submissions (Guidance). The Guidance includes important dates related to CY 2026 formulary submissions.

On April 15, 2025, the Trump administration issued an Executive Order (EO) on prescription drug costs.

On April 7, 2025, the Centers for Medicare and Medicaid Services issued the Calendar Year (CY) 2026 Rate Announcement and Final CY 2026 Part D Redesign Program Instructions.

On April 4, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (Part D Final Rule).